VX-702

VX-702 is a highly specific p38α MAPK inhibitor, 14-fold higher selectivity for the p38α than p38β. VX-702 is a small molecule investigational oral anti-cytokine therapy for treatment of inflammatory diseases, specifically rheumatoid arthritis (RA).

Price Not Available 50 mg VX-702 Supplier Page

Catalog Number	T2513
Research Area	Autophagy\|\|\|MAPK
Molecular Formula	C19H12F4N4O2
CAS#	745833-23-2
SMILES	c1cc(c(c(c1)F)N(c1nc(c(cc1)C(=O)N)c1c(cc(cc1)F)F)C(=O)N)F
Size	50 mg
Supplier Page	https://www.targetmol.com/compound/VX-702
Additional Information	https://www.targetmol.com/datasheet/T2513